Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Preprint
Data sources: ZENODO
Zenodo
Claim

PLA2G6 Inhibition for Frontotemporal Dementia via Lipid Metabolism

descriptionPublicationkeyboard_double_arrow_right Preprint Under curationPublisher:Zenodo
Authors: MedicOath Autonomous Discovery Engine;

doi: 10.5281/zenodo.19833799

PLA2G6 Inhibition for Frontotemporal Dementia via Lipid Metabolism

Abstract

PLA2G6 scores 0.88 in Open Targets and participates in glycerophospholipid metabolism (KEGG: hsa00564) and arachidonic acid metabolism (hsa00590). BROMOENOL LACTONE shows PLA2G6 inhibition (pChEMBL: 6.85). Targeting PLA2G6 could reduce neuroinflammation and lipid peroxidation in FTD.

Powered by OpenAIRE graph
Found an issue? Give us feedback